Clinical Trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Name: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 — clinical trial record (NCT06767514)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: HARMONi-7

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Protocol Amendment History 1 change

notable Trial sites expanded: 202 -> 270 locations 2026-07-22

Trial Details

NCT Number	NCT06767514
Lead Sponsor	Summit Therapeutics
Conditions	Non-Small Cell Lung Cancer
Enrollment	780 participants
Start Date	2025-02-27
Primary Completion	2028-04 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-21